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Summary In an attempt to decrease the risk of second malignancies and future infertility in children with
Hodgkin's disease (HD) while retaining acceptable remission rates, an anthracycline based regimen containing
no alkylating agent has been devised. VEEP contains vincristine, epirubicin, etoposide and prednisolone given
at 3 weekly intervals. Forty-four patients, aged 2-15 years, have been treated: ten relapsed patients and 34
previously untreated with chemotherapy (including three relapsed stage I treated initially with radiotherapy).
The median follow up for all patients is 25 months (range 6-52 months). The response rate in previously
treated patients was 80% (95% CI 44-97%) and five remain alive in remission.
The response rate in untreated patients was 88% (95% CI 72-97%) with 62% CR + CR(u) (uncertain/
unconfirmed) (95% CI 44-77%). Of four patients who had a final response of CR(u) three have relapsed at 9,
16 and 38 months. Two of the children in CR have relapsed at 6 and 16 months. The relapse free rate at 3
years is 67% (95% CI 17-82%). In this pilot study the event free survival appears somewhat poorer than
conventional combinations and further follow up is required to confirm the salvagability of relapsed patients.
The treatment of Hodgkin's disease has evolved from using
radiotherapy alone to the use of chemotherapy alone or
combination chemotherapy and radiotherapy in certain situa-
tions. The goal in treating children and young adults with
Hodgkin's disease remains the maximisation of cure rate with
minimisation of toxicity. Due to the effects of irradiation on
the growth of bone and soft tissue and potential carcino-
genicity, the tendency in paediatric practice has been to avoid
radiotherapy if possible. In the current United Kingdom
Children's Cancer Study Group (UKCCSG) this modality is
limited to patients with stage IA disease who receive no
chemotherapy or those with bulky mediastinal disease who
receive dual modality treatment (Barrett et al., 1990).
Combination chemotherapy containing mustine causes dis-
tressing nausea and vomiting and leads to infertility in adult
males and also in boys treated before puberty. In addition
there is an increased risk of second malignancy in children
treated with the combination of radiotherapy and chemo-
therapy (Donaldson & Kaplan, 1982). MOPP (mustine,
vincristine, procarbazine and prednisolone) has become the
standard treatment in both adults and children with
advanced stage disease and relapsed stage I. With MOPP
alone in patients with 'small' tumours, the disease free sur-
vival (DFS) is 90% and 87.5% in 'large' tumours, with a
follow up of 62 + months (Behiendt et al., 1987). When
combined with extended field radiation, response rates of
92% are achieved in children (Jenkin et al., 1982).
The less toxic ChlVPP evolved to replace MOPP, using
chlorambucil instead of mustine and vinblastine instead of
vincristine. At the same time irradiation fields and doses of
radiation were reduced (Robinson et al., 1984). Complete
remission rates remained good with 95% complete remission
(CR) rates and 5 year actuarial survival of 94% with a
relapse free survival of 82%. The UKCCSG using ChlVPP
alone or in combination with radiotherapy to the sites of
bulky mediastinal disease reported 78% disease free at 4
years (Radford et al., 1991). The use of this regimen has been
reported in adults with a complete response rate of 85%. The
risk of a secondary leukaemia was 2.7% at 10 years (Selby et
al., 1990). This regimen is also associated with infertility in
the majority of men and a minority of women (Sutcliffe,
1987).
The advantage of an anthracycline based regimen e.g.
ABVD - adriamycin, bleomycin, vincristine and dacarba-
zine, would appear to be high response rates with low relapse
rates and preservation of fertility (Santoro et al., 1987).
However, this regimen is not without potential significant
late effects, particularly bleomycin related lung toxicity
(Weiner et al., 1991) and adriamycin cardiac toxicity.
We describe the early results using the VEEP regimen -
regimen with no alkylating agent in the treatment of 44
children with Hodgkin's disease.
Material and methods
Between March 1987 and January 1990, 44 children with HD
have been treated with VEEP. This regimen consists of vin-
cristine 1.4 mg m-2, days 1 and 8, etoposide 200 mg m-2
orally for 4 days, epirubicin 40 mg m-2 as intravenous infus-
ion over 5-30min and oral prednisolone 60 mgm2 for 8
days, repeated at 3 weekly intervals. Blood counts were
monitored on days 8 and 15 and if the neutrophils were
> 1.5 x 109 1-' and platelet count was > 100 x 109 l-P' then
the dose ofetoposide was increased to a maximum of 5 days.
If the neutrophils were <0.5 x 109 1-1 or platelet count was
< 50 x 109 l-' then the dose of etoposide was decreased to 3
days. The characteristics of the chemotherapy-naive children
are shown in Table I.
Patients were seen and treated at a number of centres
around the UK: Royal Marsden Hospital (RMH), Great
Ormond St., St Bartholomews, Bristol, Cambridge, Royal
London Hospital, Sheffield, Leeds, Dublin, Birmingham
and Southampton - all contributing centres to UKCCSG
studies. Data sheets were completed by the attending
physicians and data collection and analysis was carried out
at the RMH. In the first series patients having relapsed after
chemotherapy were treated with VEEP. Thereafter, untreated
patients who did not have small volume or high cervical
stage IA or bilateral IIA disease were entered into the study.
Previously treated patients with stage IA disease who had
relapsed after radiotherapy were also included. Staging inves-
tigations included routine blood tests, chest X ray, bone
marrow and trephine (for greater than stage IA or IIA),
chest and abdominal CT scans. The histological classification
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Table I Characteristics ofpatients with no prior chemotherapy
(total 34)
Sex
Male
Female
Histology
Nodular sclerosing
Mixed cellularity
Lymphocyte depleted
Unknown
Stage
I
II
III
IV
Relapsed stage I
Symptoms
A
B
Age
< 5 years
5-10
11-16
Sites ofdisease- untreated only:
Paraortic/abdominal
Mediastinum ±nodes
Mediastinum + bone
Mediastinum + pericard
Nodal only
Thymus
19
15
17
8
1
8
4
20
5
2
3
24
10
9
15
10
4
15
4
1
9
1
of Lukes and Butler (1966) was used and staging was accord-
ing to the Ann Arbor (Carbone et al., 1971) classification.
Toxicity according to the WHO scales (WHO, 1979) was
collected from data sheets or retrospectively taken from
hospital notes.
Assessments for response were made after two courses and
patients continued until a complete response (CR) was docu-
mented and then for a further two courses receiving a mini-
mum of six or a maximum of eight. In general patients with
bulky mediastinal disease or residual disease after maximum
response to VEEP were considered for radiotherapy. There
was no standard radiotherapy policy, but consistency in each
centre was encouraged. A CR was documented if there was
complete disappearance of disease by clinical and the radio-
logical methods ofchoice. Responses were termed a complete
remission (uncertain/unconfirmed) CR(u) if there was a
clinical complete remission, but still a minimal radiological
abnormality that was not biopsied (Crowther & Lister, 1990).
This was invariably mediastinal. A partial remission (PR)
was the reduction of measurable disease to 50% of the
product of the two largest perpendicular diameters. Progres-
sive disease (PD) was an increase of at least 25% in the
product of the two largest perpendicular diameters. The term
stable disease (SD) was used for disease that did not change
>25% of the original or decreased <50%. The median
duration of response for all patients was from the date of
first treatment with VEEP (even if consolidation therapy was
given after) until the date of last follow up/relapse/death.
Actuarial survival and relapse free survivals were calculat-
ed using the method of Kaplan and Meier.
Results
The characteristics of the 34 untreated patients on study are
shown in Table II. The details of the previous treatments of
the ten patients who had relapsed on previous chemotherapy
are shown in Table II. The median follow up from date of
first course of VEEP was 45.5 months (range 16-52 months)
in the relapsed patients and 26.5 months (range 6-49 months)
the previously untreated. The median number of courses
before achievement of CR was four (range 2-6) and the
median total number of courses was six (range 2-8) in both
groups.
All patients were evaluable for toxicity with detailed blood
parameters in 36/44. The median nadir neutrophil count was
0.35 x 109I-' (range 0-3.5 x 1091`). Both previously un-
treated and previously treated patients became neutropenic.
Only 20% of all patients did not at any time drop their
neutrophil count below 1091'. There were four episodes of
WHO grade 2 sepsis; one patient developed haemophilus
influenza menigitis in the previously untreated group. There
were six episodes of grade 2-3 sepsis in the previously
treated group and one episode of herpes zoster. In contrast
thrombocytopenia occurred infrequently. Only two previous-
ly untreated patients developed a platelet count less than
100 x 1091- (65 x 1091-l and 49 x 1091'), and four of the
previously treated patients developed low platelet counts (17,
20, 83, 87 x 109 1'- ). There were no complications related to
bleeding. There were two patients who could not tolerate oral
etoposide and therefore received an equivalent dose intra-
venously. All the children lost their hair and there have been
no cardiac complications to date. Most children received
their treatment at 3 weekly intervals with no delays and only
6 had a maximum of 1 week delay on at least one cycle.
All patients were evaluable for response. Of the ten
patients who relapsed on previous treatment (Table II) there
have been five CRs; two of these were consolidated by
autologous bone marrow transplantation (ABMT). There
were 3 CR(u) - 2/3 achieved a CR with ABMT and the 3rd
remains in CR(u). There were 2 PD. The overall response
rate as a second line therapy was therefore 80% (CR + CR(u),
95% CI = 44-97%). Three patients have relapsed at 8, 11
and 25 months respectively after VEEP - the latter is still
alive at 20 months in 3rd CR following asparaginase and
local irradiation - the first two have died. In this group of
previously treated patients the median duration of response
was 27 months (8-50 months) with six alive in 2nd CR.
Among the 34 chemotherapy naive patients (Tables III and
IV) there were 30 in CR, CR(u) and PR to give an overall
response rate of 88% (95% CI 72-97%). Seventeen children
Table II Details of the ten patients who have received chemotherapy prior to VEEP
Duration of Duration of
Original Sites ofdisease Relapse response Response to VEEP response
Sex Age stage at relapse Previous Tx on/off Tx (months) VEEP Further Tx (months)
1 M 7 IIA Nodes MOPP Off 48 CR 45
2 F 9 IVA Nodes Ch1VPP + RT Off 36 CR(u) ABMT 16
3 M 14 IIIA Nodes + Media ChlVPP Off 7 CR(u) ABMT + RT 50
4 F 10 IIIA Nodes ChlVPP Off 27 CR 29
5 M 9 IIIB Nodes ChIVPP Off 31 CR(u) - 25
6 M 7 IIIA Nodes RT, GRAB Off 15,17 CR ABMT 25-rell
7 M 14 IIIB Nodes Liver ChlVPP + RT Off 18 CR I l-rela
8 M 15 IIA Nodes ChlVPP + RT Off 6 CR ABMT 8-rela
9 F 14 IIA Nodes + Media ChlVPP On - PD
10 M 14 IVB Nodes effusion ChlVPP On PD
RT = Radiotherapy; GRAB = alternative chemotherapy, ABMT = autologous bone marrow transplantation; CR(u) =clinical CR
(uncertain/unconfirmed); media = mediastinal; effusion = pleural effusion; Tx = treatment; rel = relapsed; aPatient died; bPatient in 3rd CR at
20 months.758 M.E.R. O'BRIEN et al.
Table III Previously untreated patients who achieved CR + CR(u)
with VEEP
Duration of
Sites of Response VEEP response
Sex Age Stage disease to VEEP (months)
I F 2 IB N CR 12
2 M 8 IIA N CR 19
3 F 13 IIA N CR 14
4 F 6 IIA N CR 20
5 F 6 IIA N CR 16
6 F 5 IIIB N+M CR 43
7 F 5 IIIB N CR 36
8 M 13 IIA N+T CR 26
9 F 3 IIIA N+M CR 42
10M 13 IIE N+M CR 40
11 M 5 IIB M CRa 21
12 F 10 IIB N+M+B CR 10
13 F 15 IVB A CR 8
14F 5 relI A CR 41
15M 6 relI N+M CR 18
16 M 13 hIA CRU 36
M
l7bM 13 IA N CRua 38
18bM 4 IIB N+M+B CR 14
l9bM 12 IVA N+M CRu 9
20bM 4 IIA N CRua 16
2lbM 4 IA CR 4
a= + radiotherapy; CRu + CR unconfirmed/uncertain; N + nodes;
M = mediastinum; B = bone; A = abdominal; P = pericardium; SD =
stable disease; NE = too early for evaluation; NR = no response;
bRelapsed after VEEP (5/34) - all now in CR after ChIVPP.
achieved a CR and four a CR(u) giving a CR rate of 62%
(95% CI 44-77%). One of the children who achieved a CR,
received radiotherapy on completion of chemotherapy to the
sites of original bulky disease. There were four patients who
achieved a CR(u), which for practical reasons was not biop-
sied and no further treatment was given. Three of these
patients have relapsed at 9 (lymphocyte depleted histology),
16 and 38 months, and the other remains in remission at 36
months since attaining a response. The three patients who
relapsed after a CR(u) are all in CR with ChlVPP. Two
patients who achieved CR have relapsed off treatment at 4
and 14 months and are currently in remission with ChlVPP.
The three patients who achieved CR(u) all relapsed outside
the site of original disease (two had received radiotherapy to
the site of bulky disease). The other two patients who relapse
after achieving a CR both had nodal disease and relapsed in
the same nodal sites.
There were nine patients who achieved a PR (see Table
IV): two have achieved a CR(u) with radiotherapy, and
remain in remission with a follow up of 8 and 16 months;
one child achieved a CR with radiotherapy to the site of
bulky disease and remains in CR at 42 months follow up.
Three patients initially responded to VEEP achieving a PR
after two courses, but no further response to a further two
courses - all three subsequently achieved a CR with ChlVPP.
The other three patients who initially achieved PRs pro-
gressed after three, four and six courses of VEEP respectively
(PR' in Table IV). The first failed to response to ChlVPP but
achieved CR with radiotherapy and the second has achieved
remission with LOPP and ABMT, the third had progressive
disease on ChlVPP, a transient response to radiotherapy and
to high dose therapy with autograft. At reporting the child is
alive with disease.
Of the four children with PD, two achieved CR and CR(u)
with ChlVPP and radiotherapy and the other two had no
further response and died. The median duration of response
for responders in the untreated group was 16.5 months
(range 4-49 months) with 67% relapse free at 3 years
(Figure 1). Ninety-two per cent of all the untreated children
are alive at 3 years (Figure 1).
Discussion
As in adults, progress has been made in the treatment of HD
in children and now refinements of effective protocols are
required. Although the aim of decreasing toxicity is neces-
sary, it is important that HD continues to be cured. It is
therefore timely to publish these early results of a phase II
study with VEEP. In this regimen two new agents - etopo-
side and epiadriamycin - have been introduced into the first
line treatment of Hodgkin's disease in children. Initial phase
II studies with etoposide in a low dose schedule in HD and
non Hodgkin's disease were disappointing with PR rates of
only 20%. When the dose was escalated 23% CR and 38%
PR was achieved including three patients who had failed
both ChlVPP and ABVD (Taylor & Homes, 1982). A variety
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Figure 1 Actuarial survival and relapse free survival in 34
chemotherapy naive patients.
Table IV Previously untreated patients who did not achieve a complete remission with VEEP
Duration of
Sites of Response Further response
Sex Age Stage disease to VEEP treatment Response (months)
22 M 8 rel I M PR RT CRu 42
23 F 4 IIA N+M PR RT CR 16
24 M 7 IIA N+M PR RT CRu 8
25 F 13 IIA N+M PR ChIVPP CR 12
26 M 15 IIIA N+P PR ChlVPP CR 13
27 F 9 IIA N+M PR ChlVPP CR 8
28a M 4 IIB N+M PR ChIVPP NR 8
RT CR
29a M 8 IIIB N+M+A PR LOPP + ABMT CR 8
30a M 10 IIA N+M PR ChlVPP PD 15b
RT + ABMT NR
31a M 3 IIA M+P PD ChlVPP + RT CR 34
32a F 13 IIB N+M PD ChIVPP + RT CRu 17
33a
M 15 IVA M+B PD ChlVPP PD 13 died
34a F 9 IA M PD ChlVPP PD 6 died
aFailed to respond or progressed on VEEP after initial response (7/34). bAlive with disease.
a1)
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of combination regimens incorporating etopside have been
studied in pretreated patients. For example, HOPE-Bleo pro-
duced 48% CR and 28% PR (Perren et al., 1990) in relapsed
heavily pretreated patients with HD. Epirubicin has activity
equal to that of doxorubicin when used in combination with
cyclophosphamide, vincristine, bleomycin and prednisolone
in the treatment of non Hodgkin's lymphoma (De Lena et
al., 1987). In addition epirubicin is reported to have less
cardiotoxic effects than doxorubicin (Neri et al., 1989).
The VEEP regimen has predictable and manageable tox-
icities, is easy to administer as an outpatient and should
decrease the incidence of infertility and 2nd malignancies.
The latter advantages will obviously take many years before
they are confirmed. With regard to potential late effects from
the VEEP regimen, recent reports of secondary myeloid leu-
kaemia are obviously of concern (Pui et al., 1989; Pedersen
Bjergaard et al., 1991). It is clear from a review of reported
cases that almost all were associated with high doses of
epipodophyllotoxin and a number had also received alkylat-
ing agents (Whitlock et al., 1991). It is likely that the total
dose of etoposide used in the VEEP regimen will be safer as
appears the case in non-pretreated germ cell tumour patients
(Pedersen Bjergaart et al., 1991).
As a salvage regimen in previously treated patients VEEP
had a response rate of 80%, six out of eight remaining
disease free at a median follow up of 45.5 months (range
16-52 months). A point of some concern, however, is the
response and relapse rate in previously untreated patients.
The overall response rate of 88% in previously untreated
patients is as reported in other series allowing for the small
numbers (Robinson et al., 1984). The low CR rate with
chemotherapy alone is at least in part due to the routine use
of CT scanning rather than X-ray as in older series. How-
ever, three initial responders progressed on treatment, and
four others failed to respond resulting in a VEEP failure rate
of 21%. In Ekert's series (1988) only 4/19 with bulky media-
stinal disease who received MOPP or ChVPP achieved CR
on CT at the end of treatment although 14 resolved subse-
quently without irradiation. Similarly, with modern imaging
techniques 20/62 children (32%) failed to achieve CR after 4
MOPP/4 ABVD although most of these were found to be
biopsy negative (Weiner et al., 1991). At a median follow up
of 26.5 months there have been five relapses (at 6, 9, 16, 16
and 38 months) and two deaths among the non-responders to
give a relapse free rate of 67% at 3 years. It will be impor-
tant to follow up this group of patients for a longer period of
time for late relapses. The 5 year relapse free rates in children
treated with ChlVPP + radiotherapy to bulky mediastinal
disease from the UKCCSG are 80% and 75% respectively
for stage II and III disease (Radford, 1991). Ekert et al.
reported on 53 children treated with MOPP or ChlVPP only;
the overall survival at 45 months follow up is 94% with 8%
treatment failure (Ekert et al., 1988). The results from the
French Cooperative Study comparing four courses of ABVD
to two courses of MOPP + two courses of ABVD followed
by 20 Gray radiotherapy to good responders to chemo-
therapy has now a median follow up of 30 months. At 4
years the disease free survival is 88% overall with 95% stage
IA and IIA disease free, 92% stage IB, IIB, III and 53%
stage IV disease. There was no difference between the two
chemotherapy regimens. This study included a large number
of patients and reported a high disease free survival, but all
responding patients received radiotherapy. Only eight of 30
of our responding, previously untreated patients received
radiotherapy.
A lower rate of response or relapse free survival than
previously reported would be acceptable if most patients
were spared radiotherapy and an alkylating agent and those
who relapsed could be successfully salvaged. This strategy
would be unacceptable if either there was a low second CR
rate or if the late effects of second line therapy combining
radiation and chemotherapy were major and involved a
significant proportion of patients.
There are few reported series of the salvage rate with
different regimens in Hodgkin's disease. Primarily resistant
disease or patients who relapse within a year of primary
therapy have a poor response to salvage therapy with a
probability of less than 20% chance of remaining disease free
2 years from the salvage therapy (James et al., 1990). In our
series of 34 previously untreated patients there have been two
deaths with a median follow up of 26.5 months (range 6-49
months). Of the seven patients who had primary resistant
disease or initial Pr and then PD, there have been four who
achieved Cr with ChlVPP (x 2), LOPP (x 1) and radio-
therapy (x 1). The follow up from the time of diagnosis in
these children are respectively 8, 8, 17 and 34 months. The
remaining three patients did not respond to subsequent treat-
ment and two have died, one is alive with disease.
Of the five children who relapsed, 2nd line ChlVPP has
resulted in CR in all. It would therefore appear that most, if
not all who relapse after an initial remission will achieve a
second CR but only further follow up will show whether
these children ultimately have as good an outcome as in
historic series. As expected the efficacy of second line treat-
ment is poorer in those who initially fail or progress on
treatment. The high relapse rate in the children with CR(u)
suggests that perhaps they should receive further treatment.
Radford et al. described a group of 110 patients with media-
stinal HD and showed that in those treated by chemotherapy
alone, a residual abnormality was associated with a signi-
ficantly higher relapse rate than those treated with a com-
bined modality (Radford et al., 1988). Two of the three
patients treated with VEEP who achieved a CR(u) and subse-
quently relapsed did in fact receive mediastinal radiation and
both relapsed in the abdomen. Our proposed strategy is that
all patients with residual mediastinal disease should be biop-
sied and radiation withheld in the absence of histologically
proven disease.
It is too early to draw firm conclusions from these results
but further follow up will show whether or not salvageable
relapse in a minority is an acceptable price to be paid for
avoiding late sequelae in the majority.
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